Preliminary results support the further development of combined immune checkpoint inhibitor neoadjuvant therapy in patients with localised or locoregionally advanced urothelial cancer

Phase II CLAP trial data indicate the benefit of combining camrelizumab and apatinib for the second- and later-line treatment of metastatic or recurrent cervical cancer

A chart review points to an increased recurrence risk for HER2-positive breast cancer patients who have intervals of 6 weeks or more in their scheduled trastuzumab doses

A large case series supports a postoperative multi-fraction stereotactic radiotherapy approach to brain metastases

Locoregional recurrence is more common with cetuximab than cisplatin for patients undergoing radiotherapy for stage III–IV head and neck squamous cell carcinoma

Oncological outcomes are similar after immediate breast reconstruction or conventional mastectomy for breast cancer patients given neoadjuvant chemotherapy

Endometrial cancer patients who maintain high levels of recreational physical activity may have better overall survival than those with lower levels

Meta-analysis points to a significant survival gain with the use of CDK4/6 inhibitors alongside endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer